Milestone Pharmaceuticals (MIST) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Milestone Pharmaceuticals has announced its second quarter financial results, revealing a cash reserve sufficient to fund operations through 2026 and the FDA’s acceptance of their new drug, CARDAMYST™, for PSVT, with a potential launch in 2025. Additionally, preparations for a Phase 3 study in AFib-RVR are underway, reflecting the company’s ongoing strategic advancements in its drug development pipeline.
For further insights into MIST stock, check out TipRanks’ Stock Analysis page.
